The money will be put towards expanding its toxicology lab in Beijing, in addition to further growing its US operations, which consists of a headquarters in California and a facility in Maryland.
In a statement, the company said that the funding will also provide it with the flexibility to consider acquisitions that would enhance its facilities or capabilities.
Bridge was asked by Outsourcing-pharma.com to elaborate on the nature of its latest expansion plans but failed to do so.
The firm's strategy involves delivering preclinical services in China at "significant savings", while providing a US-based service for clients that prefer this option.
As such, it has been making ongoing efforts to enhance its China capabilities and this is the third round of funding the company has received, bringing the total to $57m.
$35m of this was raised in February last year, also to accelerate growth of its preclinical operations in China, part of which involved constructing a second vivarium. Bridge claims to now operate the largest vivarium and US-level compliant pharmaceutical drug testing lab in the country.
At the time, the firm had also recently completed the acquisition of the Preclinical Division of Gene Logic, which was also funded by the cash injection.
China is growing in popularity as a destination for outsourcing stages of the drug development process and in the preclinical arena it is particularly attractive due to the country's efforts of late to specialise in the field, and the low costs involved.
Bridge has to compete for business in the country with domestic rivals WuXi PharmaTech and ShangPharma that are also attracting new investment and new business and growing larger by the month.
In February last year the firm launched a new training scheme between its facilities in the US and China to enable its employees to cross train in both labs - a potential competitive advantage for a contract research organisation (CRO) in China.
"The first thing that any prospective client looks at is our training records so the advantage is critical," Glenn Rice, Bridge's (former) CEO, told Outsourcing-Pharma.com at the time.
The Visiting Scholar Programme offered by the company was the first of its kind in the preclinical CRO industry and the company then claimed to be the only pre-clinical CRO to develop drugs to US level standards in Asia.
